Tasnuva Kabir
My aim is to become an expert career biomedical scientist in liver disease, using cutting edge technologies to discover new ways to treat liver cancer. To achieve my aim, I initially completed PhD generating expertise in understanding the cancer microenvironment after completing my medical studies. During my PhD I worked on the DNA damage response (DDR) and acquisition of senescence and senescence associated secretory phenotype (SASP) in cancer-associated fibroblasts. I investigated the mechanism by which small non-coding RNAs called microRNAs regulate the secretome of senescent fibroblasts that permit cancer progression. In the Harry Perkins Institute of Medical Research, I am building a strong foundation of experience in liver cancer working on the mechanisms that underlie the development of treatment resistance, in order to identify new potential drug pathways. In addition, I have been developing novel synthetic RNA-based drugs, modified microRNAs, to treat drug resistant liver cancer. I am very interested in studying the roles of non-coding RNAs, such as microRNAs as well as other RNAs, in modulating chronic inflammatory diseases, such as NASH (non-alcoholic steatohepatitis), and cancer metastasis. My longer-term goal is to develop a novel therapy that could be translated into an early phase clinical trial in liver cancer, and if successful make a substantial difference to the outcome of these patients.
(Sun 16:00-17:50 Elston Room) Session 8: Pancreas & Cancer - Plenary
(17:40-17:50) GRW010 — Caving & Axing the Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma – New Insights to Overcome Therapeutic Resistance
(back to speakers)
|
.jpg)